87 related articles for article (PubMed ID: 2540964)
1. Growth stimulation of human epidermal cells by urokinase is restricted to the intact active enzyme.
Kirchheimer JC; Christ G; Binder BR
Eur J Biochem; 1989 Apr; 181(1):103-7. PubMed ID: 2540964
[TBL] [Abstract][Full Text] [Related]
2. Proliferation of a human epidermal tumor cell line stimulated by urokinase.
Kirchheimer JC; Wojta J; Christ G; Binder BR
FASEB J; 1987 Aug; 1(2):125-8. PubMed ID: 3038646
[TBL] [Abstract][Full Text] [Related]
3. Structural requirements for the growth factor activity of the amino-terminal domain of urokinase.
Rabbani SA; Mazar AP; Bernier SM; Haq M; Bolivar I; Henkin J; Goltzman D
J Biol Chem; 1992 Jul; 267(20):14151-6. PubMed ID: 1321137
[TBL] [Abstract][Full Text] [Related]
4. Differential inhibition of endothelial cell proliferation and migration by urokinase subdomains: amino-terminal fragment and kringle domain.
Kim KS; Hong YK; Lee Y; Shin JY; Chang SI; Chung SI; Joe Y
Exp Mol Med; 2003 Dec; 35(6):578-85. PubMed ID: 14749538
[TBL] [Abstract][Full Text] [Related]
5. Growth factor-like effect of urokinase type plasminogen activator in human renal cells.
He CJ; Rebibou JM; Peraldi MN; Meulders Q; Rondeau E
Biochem Biophys Res Commun; 1991 May; 176(3):1408-16. PubMed ID: 1645544
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-type and tissue-type plasminogen activators as growth factors of human fibroblasts.
De Petro G; Copeta A; Barlati S
Exp Cell Res; 1994 Jul; 213(1):286-94. PubMed ID: 8020601
[TBL] [Abstract][Full Text] [Related]
7. A hybrid protein of urokinase growth-factor domain and plasminogen-activator inhibitor type 2 inhibits urokinase activity and binds to the urokinase receptor.
Ballance DJ; Marshall JM; Cottingham IR; Steven J; Berry SJ; Cederholm-Williams SA; Goodey AR; Courtney M
Eur J Biochem; 1992 Jul; 207(1):177-83. PubMed ID: 1321039
[TBL] [Abstract][Full Text] [Related]
8. Urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes are not internalized upon binding to the urokinase-type-plasminogen-activator receptor in THP-1 cells. Interaction of urokinase-type plasminogen activator/type-2 plasminogen-activator inhibitor complexes with the cell surface.
Ragno P; Montuori N; Rossi G
Eur J Biochem; 1995 Oct; 233(2):514-9. PubMed ID: 7588796
[TBL] [Abstract][Full Text] [Related]
9. Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes.
Stoppelli MP; Corti A; Soffientini A; Cassani G; Blasi F; Assoian RK
Proc Natl Acad Sci U S A; 1985 Aug; 82(15):4939-43. PubMed ID: 2991901
[TBL] [Abstract][Full Text] [Related]
10. Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).
Magdolen V; Bürgle M; de Prada NA; Schmiedeberg N; Riemer C; Schroeck F; Kellermann J; Degitz K; Wilhelm OG; Schmitt M; Kessler H
Biol Chem; 2001 Aug; 382(8):1197-205. PubMed ID: 11592401
[TBL] [Abstract][Full Text] [Related]
11. Interaction between kringle and growth-factor-like domains in the urokinase molecule: possible role in stimulation of chemotaxis.
Stepanova VV; Beloglazova IB; Gursky YG; Bibilashvily RS; Parfyonova YV; Tkachuk VA
Biochemistry (Mosc); 2008 Mar; 73(3):252-60. PubMed ID: 18393759
[TBL] [Abstract][Full Text] [Related]
12. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.
Resnati M; Guttinger M; Valcamonica S; Sidenius N; Blasi F; Fazioli F
EMBO J; 1996 Apr; 15(7):1572-82. PubMed ID: 8612581
[TBL] [Abstract][Full Text] [Related]
13. Structure of human urokinase plasminogen activator in complex with its receptor.
Huai Q; Mazar AP; Kuo A; Parry GC; Shaw DE; Callahan J; Li Y; Yuan C; Bian C; Chen L; Furie B; Furie BC; Cines DB; Huang M
Science; 2006 Feb; 311(5761):656-9. PubMed ID: 16456079
[TBL] [Abstract][Full Text] [Related]
14. Cellular receptor for urokinase-type plasminogen activator: protein structure.
Behrendt N; Ploug M; Rønne E; Høyer-Hansen G; Danø K
Methods Enzymol; 1993; 223():207-22. PubMed ID: 8271954
[No Abstract] [Full Text] [Related]
15. Epitope mapping of the anti-urokinase monoclonal antibody 5B4 by isolated domains of urokinase.
Corti A; Sarubbi E; Soffientini A; Nolli ML; Zanni A; Galimberti M; Parenti F; Cassani G
Thromb Haemost; 1989 Nov; 62(3):934-9. PubMed ID: 2480654
[TBL] [Abstract][Full Text] [Related]
16. Influence of urokinase on cell proliferation and invasion.
Binder BR
Blood Coagul Fibrinolysis; 1990 Dec; 1(6):717-20. PubMed ID: 1966799
[TBL] [Abstract][Full Text] [Related]
17. Blockage of the urokinase receptor on the cell surface: construction and characterization of a hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin.
Lu H; Yeh P; Guitton JD; Mabilat C; Desanlis F; Maury I; Legrand Y; Soria J; Soria C
FEBS Lett; 1994 Dec; 356(1):56-9. PubMed ID: 7988721
[TBL] [Abstract][Full Text] [Related]
18. Amino-terminal fragment of urokinase inhibits tumor cell invasion in vitro and in vivo: respective contribution of the urokinase plasminogen activator receptor-dependent or -independent pathway.
Li H; Soria C; Griscelli F; Opolon P; Soria J; Yeh P; Legrand C; Vannier JP; Belin D; Perricaudet M; Lu H
Hum Gene Ther; 2005 Oct; 16(10):1157-67. PubMed ID: 16218777
[TBL] [Abstract][Full Text] [Related]
19. The structure basis of the poor fibrin specificity of urokinase (II)--The inhibition of urokinase A chain 149-157 on the fibrin stimulated activation of plasminogen by tissue type plasminogen activator.
Song A; Liu JN; Yu RR; Cui DF; Zhou TM; Cui HR; Zhu DX
Sci China B; 1992 Aug; 35(8):966-73. PubMed ID: 1338753
[TBL] [Abstract][Full Text] [Related]
20. Amino-terminal fragment of urokinase-type plasminogen activator inhibits HIV-1 replication.
Wada M; Wada NA; Shirono H; Taniguchi K; Tsuchie H; Koga J
Biochem Biophys Res Commun; 2001 Jun; 284(2):346-51. PubMed ID: 11394884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
